The therapeutic utility of DNAzymes has been explored in various disease contexts, including targeting VEGF in age-related macular degeneration [38], c-Jun in skin cancer [39], and BCL-2 in hematologic malignancies [40]. Here, JUN is linked to hematologic disorder.